Abstract
As an emerging virus, SARS-CoV-2 and the risk of transmission during air travel is of high interest. This paper estimates the probability of an infectious index passenger in the air travel system transmitting the SARS-CoV-2 virus to a fellow passenger during air travel. Literature was reviewed from May–September 2020 to identify COVID-19 cases related to the air travel system. The studies were limited to publicly available literature for passengers starting in January 2020; studies on other persons such as flight crews were not reviewed. A novel quantitative approach was developed to estimate air travel transmission risk that considers secondary cases, the overall air travel passenger population, and two correction factors for asymptomatic transmission and underreporting. There were at least 2866 index infectious passengers documented to have passed through the air travel system in a 1.4 billion passenger population. With correction factors, the global risk of transmission during air travel is 1:1.7 million. Uncertainty in the correction factors and a 95% credible interval indicate risk ranges from 1 case for every 712,000 travelers to 1 case for every 8 million travelers. The risk of COVID-19 transmission on an aircraft is low, even with infectious persons onboard.
Competing Interest Statement
All authors are employees of The Boeing Company.
Funding Statement
This work was supported by The Boeing Company. No additional external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All inputs and outputs reported in this paper are provided in the main text. Researchers are encouraged to contact the corresponding author for clarifications, advice on data utilization, and collaborations.
